|
KR100816621B1
(ko)
|
1997-04-07 |
2008-03-24 |
제넨테크, 인크. |
항-ｖｅｇｆ 항체
|
|
ATE241380T1
(de)
|
1999-03-26 |
2003-06-15 |
Regeneron Pharma |
Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
|
|
US6455035B1
(en)
|
1999-03-26 |
2002-09-24 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
|
EP1046715A1
(en)
|
1999-04-23 |
2000-10-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
|
|
US20020068066A1
(en)
*
|
1999-08-20 |
2002-06-06 |
Wenyuan Shi |
Method for the treatment and prevention of dental caries
|
|
AU784231B2
(en)
|
2000-06-23 |
2006-02-23 |
Schering Aktiengesellschaft |
Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
|
|
CN1318093C
(zh)
|
2001-09-28 |
2007-05-30 |
参天制药株式会社 |
含与聚乙二醇结合的药物的眼组织注射剂
|
|
US20050260132A1
(en)
|
2001-10-17 |
2005-11-24 |
Daniel Chin |
Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
|
|
DE60217711T2
(de)
|
2001-12-04 |
2007-11-15 |
Develogen Aktiengesellschaft |
Ptp10d nukleinsäuren und peptide in der regulation von energie-homeostase
|
|
US20030215899A1
(en)
|
2002-02-13 |
2003-11-20 |
Ceptyr, Inc. |
Reversible oxidation of protein tyrosine phosphatases
|
|
WO2003092611A2
(en)
|
2002-05-03 |
2003-11-13 |
Regeneron Pharmaceuticals, Inc. |
Methods of inducing formation of functional and organized lymphatic vessels
|
|
US7226755B1
(en)
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
|
US7507568B2
(en)
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
|
CA2599606A1
(en)
*
|
2005-02-23 |
2006-08-31 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
|
US20070154482A1
(en)
|
2005-09-12 |
2007-07-05 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
|
WO2007041317A2
(en)
|
2005-09-29 |
2007-04-12 |
Viral Logic Systems Technology Corp. |
Immunomodulatory compositions and uses therefor
|
|
EP1962903B1
(en)
|
2005-12-15 |
2013-03-13 |
MedImmune Limited |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
|
|
EP1981520A2
(en)
|
2006-01-30 |
2008-10-22 |
(OSI) Eyetech, Inc. |
Combination therapy for the treatment of neovascular disorders
|
|
DK2368914T3
(en)
|
2006-03-10 |
2019-03-04 |
Wyeth Llc |
Anti-5T4 antibodies and uses thereof
|
|
WO2007113648A2
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
RU2494108C2
(ru)
*
|
2006-04-07 |
2013-09-27 |
Аерпио Терапетикс, Инк. |
Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
|
|
US7622593B2
(en)
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US20130023542A1
(en)
|
2006-06-27 |
2013-01-24 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7795444B2
(en)
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US10259860B2
(en)
|
2007-02-27 |
2019-04-16 |
Aprogen Inc. |
Fusion proteins binding to VEGF and angiopoietin
|
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
|
JP2010531896A
(ja)
|
2007-06-26 |
2010-09-30 |
チルドレンズ メディカル センター コーポレーション |
治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム
|
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
WO2009154026A1
(ja)
|
2008-06-20 |
2009-12-23 |
国立大学法人岡山大学 |
石灰化小球に対する抗体及びその用途
|
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
|
BRPI0921469B1
(pt)
|
2008-11-03 |
2022-01-18 |
Molecular Partners Ag |
Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
|
|
DK2385763T3
(en)
|
2009-01-12 |
2018-07-16 |
Aerpio Therapeutics Inc |
METHODS OF TREATING VASCULAR LEAK SYNDROME
|
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
|
WO2010097800A1
(en)
|
2009-02-26 |
2010-09-02 |
Muhammad Abdulrazik |
Synergistic combination of bioactive compounds for lowering of intraocular pressure
|
|
WO2010111180A1
(en)
*
|
2009-03-24 |
2010-09-30 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against light and uses thereof
|
|
ES2726946T3
(es)
|
2009-07-06 |
2019-10-10 |
Aerpio Therapeutics Inc |
Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
|
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
AU2010325969B2
(en)
|
2009-12-02 |
2016-10-20 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
|
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
|
US20180092883A1
(en)
|
2010-10-07 |
2018-04-05 |
Aerpio Therapeutics, Inc. |
Phosphatase inhibitors for treating ocular diseases
|
|
NZ610230A
(en)
|
2010-10-07 |
2015-07-31 |
Aerpio Therapeutics Inc |
Compositions and methods for treating ocular edema, neovascularization and related diseases
|
|
JP2014508749A
(ja)
|
2011-02-11 |
2014-04-10 |
サイヴィーダ ユーエス，インコーポレイテッド |
抗浮腫治療薬を使用する黄斑浮腫の治療方法
|
|
WO2012158818A2
(en)
*
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
WO2013056240A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome and cancer
|
|
BR112014008759A8
(pt)
|
2011-10-13 |
2017-09-12 |
Aerpio Therapeutics Inc |
Tratamento de doença ocular
|
|
SG11201408538PA
(en)
|
2012-07-13 |
2015-02-27 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
MX373894B
(es)
|
2012-11-08 |
2020-07-09 |
Clearside Biomedical Inc |
Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
|
|
AU2014233363B2
(en)
|
2013-03-15 |
2017-06-29 |
EyePoint, Inc. |
Compositions, formulations and methods for treating ocular diseases
|
|
US20150050277A1
(en)
|
2013-03-15 |
2015-02-19 |
Aerpio Therapeutics Inc. |
Compositions and methods for treating ocular diseases
|
|
US20160137717A1
(en)
|
2013-06-20 |
2016-05-19 |
Gabriela Burian |
Use of a vegf antagonist in treating choroidal neovascularisation
|
|
EP3010526A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Use of a vegf antagonist in treating macular edema
|
|
EP3019526A1
(en)
|
2013-07-11 |
2016-05-18 |
Novartis AG |
Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
|
|
RU2676303C2
(ru)
|
2013-07-11 |
2018-12-27 |
Новартис Аг |
Использование антагониста vegf для лечения ретролентальной фиброплазии
|
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
|
CA2926853C
(en)
|
2013-10-18 |
2022-04-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
|
|
ES2866935T3
(es)
*
|
2014-01-10 |
2021-10-20 |
Anaptysbio Inc |
Anticuerpos dirigidos contra interleucina-33 (IL-33)
|
|
WO2015109898A1
(zh)
|
2014-01-24 |
2015-07-30 |
上海恒瑞医药有限公司 |
VEGF与PDGFRβ双特异性融合蛋白及其用途
|
|
EP3116503A4
(en)
|
2014-03-14 |
2017-08-23 |
Aerpio Therapeutics, Inc. |
Hptp-beta inhibitors
|
|
US9719135B2
(en)
*
|
2014-07-03 |
2017-08-01 |
Mannin Research Inc. |
Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
|
|
WO2016022813A1
(en)
|
2014-08-07 |
2016-02-11 |
Aerpio Therapeutics, Inc. |
Combination of immunotherapies with activators of tie-2
|
|
BR112017003263A2
(pt)
|
2014-09-16 |
2017-11-28 |
Ovascience Inc |
anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
|
|
WO2016049183A1
(en)
*
|
2014-09-24 |
2016-03-31 |
Aerpio Therapeutics, Inc. |
Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
|
|
TWI806150B
(zh)
|
2014-11-07 |
2023-06-21 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
KR102427117B1
(ko)
|
2015-04-02 |
2022-07-29 |
몰리큘라 파트너스 아게 |
혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
|
|
US11091559B2
(en)
|
2015-08-27 |
2021-08-17 |
Celldex Therapeutics, Inc. |
Anti-ALK antibodies and methods for use thereof
|
|
ES2894802T3
(es)
|
2015-09-23 |
2022-02-15 |
Aerpio Pharmaceuticals Inc |
Activadores de Tie-2 para su uso en el tratamiento de la presión intraocular
|
|
PE20181363A1
(es)
|
2015-09-23 |
2018-08-27 |
Genentech Inc |
Variantes optimizadas de anticuerpos anti-vegf
|
|
US10894823B2
(en)
|
2016-03-24 |
2021-01-19 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
|
BR112019001206A2
(pt)
|
2016-07-20 |
2019-06-25 |
Aerpio Therapeutics Inc |
anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
|
|
WO2020068653A1
(en)
|
2018-09-24 |
2020-04-02 |
Aerpio Pharmaceuticals, Inc. |
MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
|